Rare disease-focused REGENXBIO hit the ground running in 2022 with its developmental programs for Duchenne Muscular Dystrophy and wet age-related macular degeneration. The Maryland-based company received clearance from the U.S. Food and Drug Administration to initiate a first-in-human study of its gene therapy for the rare form of muscular dystrophy.
REGENXBIO Starts 2022 by Moving DMD Gene Therapy into the Clinic and Advancing AbbVie Partnership
![REGENXBIO Logo](https://biobuzz.io/wp-content/uploads/2021/11/regenxbio-300x300.png)